Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05595993
Other study ID # H-21067676
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 25, 2022
Est. completion date December 31, 2023

Study information

Verified date February 2023
Source Danish Headache Center
Contact Hakan Ashina, MD
Phone +4528102495
Email haakan.ashina@regionh.dk
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To investigate whether cilostazol (phosphodiesterase 3 inhibitor) induces headache with migraine-like features in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).


Recruitment information / eligibility

Status Recruiting
Enrollment 21
Est. completion date December 31, 2023
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - Age 18 to 65 years of age upon entry into screening - History of persistent headache attributed to mild traumatic injury to the head for = 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3) - = 4 monthly headache days on average across the 3 months prior to screening - Provision of informed consent prior to initiation of any study-specific activities/procedures. Exclusion Criteria: - > 1 mild traumatic injury to the head - History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache) - History of moderate or severe injury to the head - History of whiplash injury - History of craniotomy - History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion - The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior - Female subjects of childbearing potential with a positive pregnancy test during any study visit - Cardiovascular disease of any kind, including cerebrovascular diseases - Hypertension (systolic blood pressure of =150 mmHg and/or diastolic blood pressure of =100 mmHg) prior to the start of infusion on the experimental day - Hypotension (systolic blood pressure of =90 mmHg and/or diastolic blood pressure of =50 mmHg) - Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion - Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start - Baseline headache intensity of >3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache) - Baseline headache with migraine-like features or self-reported baseline headache that mimics the subjects' usual headache with migraine-like features

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cilostazol
Study participants will be allocated to receive oral administration of 200 mg cilostazol.
Placebo
Study participants will be allocated to receive oral administration of placebo.

Locations

Country Name City State
Denmark Danish Headache Center Copenhagen

Sponsors (1)

Lead Sponsor Collaborator
Danish Headache Center

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of Migraine-Like Headache Difference in incidence of headache with migraine-like features (0 to 12 hours) between cilostazol and placebo. 12 Hours
Secondary Headache Intensity Scores Difference in area under the curve (AUC) for headache intensity scores (0 to 12 hours) between cilostazol and placebo. 12 Hours
See also
  Status Clinical Trial Phase
Recruiting NCT04369729 - Investigate the Mechanisms, Predictors, and Prevention of Persistent Post-Traumatic Headache
Completed NCT03588364 - The Role of Osteopathic Manipulation in the the Management of Post-traumatic Migraine N/A
Recruiting NCT05378074 - Hypersensitivity to Opening of BKCa Channels in Post-Traumatic Headache N/A
Recruiting NCT05328635 - Post-traumatic Headache Multidisciplinary Study
Completed NCT04776304 - Art Therapy qEEG Study for Service Members With a Traumatic Brain Injury and Posttraumatic Stress Symptoms N/A
Recruiting NCT04614922 - Acceptance and Commitment Therapy-based Rehabilitation of Post-concussion Symptoms N/A
Completed NCT03674398 - Aerobic Exercise and Cognitive Training Effects on Postconcussive Symptomology N/A
Completed NCT02965027 - Prazosin for Post-Concussive Headaches Phase 4
Active, not recruiting NCT05635656 - Digital Solutions for Concussion N/A
Recruiting NCT06015451 - Exercise in Postconcussion Symptoms and Posttraumatic Headache N/A
Recruiting NCT04906603 - Theta Burst Stimulation for Headaches After Traumatic Brain Injury N/A
Terminated NCT01053507 - Treximet for Prevention of Post Traumatic Headache Associated With Cognitive Dysfunction Phase 4
Completed NCT02419131 - Cognitive-Behavior Therapy for Posttraumatic Headache N/A
Terminated NCT03806985 - Effects of Psilocybin in Concussion Headache Phase 1
Completed NCT05243953 - Hypersensitivity to Opening of ATP-Sensitive Potassium Channels in Post-Traumatic Headache N/A
Completed NCT03056352 - Metoclopramide for Post-Traumatic Headache. A Pilot Study Phase 1/Phase 2
Recruiting NCT06132529 - A Study to Evaluate Biomarker Signature to Predict the Persistence of Post-traumatic Headache
Completed NCT01854385 - Sumatriptan as Treatment for Post-traumatic Headache Phase 2
Completed NCT03523923 - TBI Care: Collaborative Care for Pain After Traumatic Brain Injury (TBI) N/A
Recruiting NCT05378061 - Hypersensitivity to PACAP-38 in Post-Traumatic Headache N/A